Skip to main content
Equibles
ERAS logo

ERAS · Erasca, Inc.

Track ERAS — free

Use ERAS with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ERAS

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$18.38 +0.52 (+2.91%) At close · Aug 14
Market Cap
$6.43B
Shares
349.76M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$18.38 Open$17.50 Day$17.30–18.47 52W close$1.43–22.47 Avg vol 30d4.2M Short int30.0M · 8.6% float · 7.3d Short vol37% Last earningsMay 8, 2024 DataJul 2021–Aug 2026 Filing10-Q · Aug 11

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 11, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +57%
above
Price vs 50-day avg +7%
above
RSI (14) 52
neutral
MACD trend Negative
52-week position 81%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −4%
trailing
6-month return +41%
trailing
YTD return +394%
this year
Relative strength +27%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +62 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.56% of float · ▼ -2.6% MoM · 7.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
256 holders — near 3-yr high, broad support
Squeeze score 81
high risk · 0–100
Fundamentals
Strong
EPS growth +36%
Y/Y
Free cash flow $-95.6M
Balance sheet $73.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 104%
annualized · 1-yr
Max drawdown −59%
past year
ATR 6.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+57% Bullish
Price vs 50-day avg
+7% Bullish
RSI (14)
52 Neutral
MACD trend
Negative Bearish
52-week position
81% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $17 › 200d $12 — 50d above 200d
Institutional flow Accumulating
+13% holders QoQ · +62 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.56% of float · ▼ -2.6% MoM · 7.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
256 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $18 · 81% Range high $22
vs 200-day avg +57% vs 50-day avg +7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
cash, cash equivalents and marketable securities $341.8M year ended December 31, 2025 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ERAS
Erasca, Inc.
this stock
$6.43B +394.1% — — 8.6%
ONC
BeOne Medicines Ltd.
 $513.62B +14.4% +22179.2% 789.7 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $128.19B +11.6% +46.2% 29.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.72B +4.1% +20.8% 19.9 3.3%
ARGX
Argenx SE
 $52.94B +1.2% — — 2.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
256
% held
82.5%
Net QoQ
+12.6M sh
Top holder
Jonathan E. Lim
Held Float
View
Held by Funds
Fund positions
229
View
Short & Settlement
Short Interest Falling
Shares short
30.0M
Days to cover
7.3d
Change
-812.8K sh
View
Short Volume
Short vol %
37%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
202.0K
Value
$3.8M
As of
Jul 9, 2026
View
Off-Exchange
Off-exchange %
47.4%
Week of
Jul 6, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-124.5M
EPS diluted
$-0.44
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
18
View
Proposed Sales
Value
$1.3M
Shares
80.0K
Filed
Apr 1, 2026
View
Exempt Offerings
Offering
$374.5M
Filed
Apr 30, 2020
View
Earnings & Events
Earnings Calls
Last call
May 8, 2024
View

Performance

5D 20D 120D MTD YTD
ERAS -0.2% -4.1% +41.2% +1.3% +394.1%
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -0.6% -8.6% +27.4% -2.7% +380.2%
Key facts CIK 1761918 CUSIP 29479A108 13F (30d) 248 filings 247 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)